PUBLIC PROCUREMENT NOTICEExternal opportunity
Preparing English translation…
Germany – Pharmaceutical products – Ex-Ante-Transparenzbekanntmachung § 130c Abs. 1 SGB V Arzneimittelbezeichnung: Briumvi (R) Wirkstoff: Ublituximab ATC-Code: L04AG14
Arzneimittelrabattvertrag § 130c Abs. 1 SGB V Arzneimittelbezeichnung: Briumvi (R) Wirkstoff: Ublituximab ATC-Code: L04AG14 Procedure: neg-wo-call. Review the original TED notice for the complete requirement, lots, amendments and attachment
Opportunity description
Arzneimittelrabattvertrag § 130c Abs. 1 SGB V Arzneimittelbezeichnung: Briumvi (R) Wirkstoff: Ublituximab ATC-Code: L04AG14 Procedure: neg-wo-call. Review the original TED notice for the complete requirement, lots, amendments and attachments.
Buyer Sign in to view
Response deadline Sign in to view
Delivery Sign in to view
Estimated value Sign in to view
Business details are available after sign in
Codes, capabilities, evidence, buyer details and marketplace actions are withheld from the public HTML and API response.